Min J.
Min J. Kim, Daejeon KR
Patent application number | Description | Published |
---|---|---|
20140147423 | PHARMACEUTICAL COMPOSITION CONTAINING FIBULIN-3 PROTEIN AS AN ACTIVE INGREDIENT FOR INHIBITING THE GROWTH OF CANCER STEM CELLS - The present invention relates to fibulin-3 protein and a pharmaceutical composition comprising the fibulin-3 protein as an active ingredient for inhibiting the growth of cancer stem cells. More particularly, in cancer stem cells separated from H460 and A549 cells, which are non-small-cell lung cancer cells, using ALDH1 activity as a marker, fibulin-3 induces the reductions of wnt/β-catenin, MMP2 and 7, which display characteristics of cancer stem cells, thereby decreasing the activated growth and penetration of the cancer stem cells. In addition, the purified fibulin-3 protein inhibits the growth of the non-small-cell lung cancer cell line A549, the breast cancer cell line MDA-MB231, and the cancer stem cell line active ALDH1. Therefore, fibulin-3 can be valuably used as an active ingredient of the pharmaceutical composition for inhibiting the growth of cancer stem cells. | 05-29-2014 |
Min J. Lee, Jamaica Plain, MA US
Patent application number | Description | Published |
---|---|---|
20130045992 | Compositions and Methods for Enhancing Proteasome Activity - Proteinopathies result from the proteasome not acting efficiently enough to eliminate harmful proteins and prevent the formation of the pathogenic aggregates. As described herein, inhibition of proteasome-associated deubiquitinase Usp 14 results in increased proteasome efficiency. The present invention therefore provides novel compositions and methods for inhibition of Usp14, enhancement of proteasome activity and treatment of proteinopathies. | 02-21-2013 |
Min J. Lee, Jamaica Plan, MA US
Patent application number | Description | Published |
---|---|---|
20130210845 | Tricyclic Proteasome Activity Enhancing Compounds - Proteinopathies result from the proteasome not acting efficiently enough to eliminate harmful proteins and prevent the formation of the pathogenic aggregates. As described herein, inhibition of proteasome-associated deubiquitinase Usp14 results in increased proteasome efficiency. The present invention therefore provides novel compositions and methods for inhibition of Usp14, enhancement of proteasome activity and treatment of proteinopathies. | 08-15-2013 |
Min J. Song, Gyeonggi-Do KR
Patent application number | Description | Published |
---|---|---|
20140120187 | COMPOSITION FOR ACCELERATING CHANGE IN MUSCLE TYPE - The present invention provides a composition for accelerating a change in muscle type, increasing the amount of muscle, strengthening muscle, enhancing athletic abilities, reducing lipids, suppressing the accumulation of lipids, lowering blood sugar, controlling body weight or lowering body weight, containing a PPAR-δ promoter, an AMPK promoter and a PGC1-α promoter as an active ingredient | 05-01-2014 |